150 related articles for article (PubMed ID: 34567940)
1. Experience with nasogastric tube administration of tirabrutinib in the treatment of an elderly patient with primary central nervous system lymphoma.
Yoshioka H; Okuda T; Nakao T; Fujita M; Takahashi JC
Int Cancer Conf J; 2021 Oct; 10(4):290-293. PubMed ID: 34567940
[TBL] [Abstract][Full Text] [Related]
2. Experience With Tirabrutinib in the Treatment of Primary Central Nervous System Lymphoma that Is Difficult to Treat With Standard Treatment.
Yoshioka H; Okuda T; Nakao T; Fujita M; Takahashi JC
Anticancer Res; 2022 Aug; 42(8):4173-4178. PubMed ID: 35896257
[TBL] [Abstract][Full Text] [Related]
3. Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.
Okita Y; Kano-Fujiwara R; Nakatsuka SI; Honma K; Kinoshita M
Exp Hematol Oncol; 2021 Apr; 10(1):29. PubMed ID: 33902692
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
[TBL] [Abstract][Full Text] [Related]
5. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
[TBL] [Abstract][Full Text] [Related]
6. [An elderly patient with lymphoplasmacytic lymphoma successfully treated with low-dose tirabrutinib].
Yasumi M; Shiraishi K; Kamijo K; Kamae T; Karasuno T
Rinsho Ketsueki; 2023; 64(4):245-249. PubMed ID: 37121766
[TBL] [Abstract][Full Text] [Related]
7. Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
Yonezawa H; Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Aoi A; Nishikawa R
Neurooncol Adv; 2024; 6(1):vdae037. PubMed ID: 38690230
[TBL] [Abstract][Full Text] [Related]
8. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
Sasaki N; Nagane M
No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
[TBL] [Abstract][Full Text] [Related]
9. Tirabrutinib: First Approval.
Dhillon S
Drugs; 2020 Jun; 80(8):835-840. PubMed ID: 32382949
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of Primary Central Nervous System Lymphoma: Standard Treatments According to the Japanese 2019 Guideline and Novel Treatments].
Sasaki N; Nagane M
Brain Nerve; 2021 Oct; 73(10):1107-1114. PubMed ID: 34615748
[TBL] [Abstract][Full Text] [Related]
11. Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia.
Nakagawa N; Yamano R; Kajikawa S; Kondo Y; Okumura H
Leuk Res Rep; 2022; 17():100331. PubMed ID: 35669930
[TBL] [Abstract][Full Text] [Related]
12. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus.
Yamagami J; Ujiie H; Aoyama Y; Ishii N; Tateishi C; Ishiko A; Ichijima T; Hagihara S; Hashimoto K; Amagai M
J Dermatol Sci; 2021 Sep; 103(3):135-142. PubMed ID: 34376340
[TBL] [Abstract][Full Text] [Related]
15. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
Okahashi N; Uchihara M; Hoshino E
Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449
[TBL] [Abstract][Full Text] [Related]
16. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
17. A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy.
Biswas A; Adhikari N; Bakhshi S; Gopinathan VR; Sharma MC
Pediatr Neurosurg; 2019; 54(1):57-65. PubMed ID: 30669145
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).
Liu Y; Yao Q; Zhang F
Int J Oncol; 2021 Mar; 58(3):371-387. PubMed ID: 33650642
[TBL] [Abstract][Full Text] [Related]
19. Tirabrutinib hydrochloride for B-cell lymphomas.
Munakata W; Tobinai K
Drugs Today (Barc); 2021 Apr; 57(4):277-289. PubMed ID: 33851691
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma.
Alsuliman T; Belghoul M; Choufi B
Case Rep Hematol; 2018; 2018():5761627. PubMed ID: 30186643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
